Long-term follow-up of intravitreal bevacizumab in retinal arterial macroaneurysm: A case report

Shani Golan*, Daphna Goldenberg, Michaella Goldstein

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Purpose: To present the long-term effect of intravitreal bevacizumab (Avastin®) therapy in a patient suffering from retinal arterial macroaneurysm. Methods: Case report of a 72-year-old female diagnosed with retinal macroaneurysm in the superior temporal artery leading to macular edema. Functional and morphological data at baseline, 4 weeks, 2 months, and 13 months following treatment with two consecutive intravitreal bevacizumab injections are presented. Results: Best-corrected visual acuity improved from 20/160 at baseline to 20/20 at the3-months follow-up and remained stable through 13 months of follow-up. Central retinal thickness measured by optical coherence tomography decreased from 364 μm at baseline to 248 μm at the 13-months follow-up. No ocular or systemic side effects were detected. Conclusions: Intravitreal bevacizumab therapy may lead to resolution of macular edema associated with retinal macroaneurysm and consequently visual improvement. This treatment may promise a long-lasting effect but warrant further investigation in larger series.

Original languageEnglish
Pages (from-to)387-391
Number of pages5
JournalCase Reports in Ophthalmology
Issue number3
StatePublished - Sep 2011


  • Anti-VEGF therapy
  • Bevacizumab (Avastin®)
  • Macular edema
  • Retinal macroaneurysm


Dive into the research topics of 'Long-term follow-up of intravitreal bevacizumab in retinal arterial macroaneurysm: A case report'. Together they form a unique fingerprint.

Cite this